News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2024

8 November, 2024 Interim report Q3 2024 News English Regulatory MAR Report Interim Q3 IR Optional
5 November, 2024 Invitation to Presentation of Egetis’ Third Quarter 2024 Report News Corporate Information Presentation English IR Optional
31 October, 2024 Egetis’ Nomination Committee for the 2025 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
28 October, 2024 Egetis Therapeutics publishes prospectus for admission to trading of shares on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
25 October, 2024 Bulletin from Egetis Therapeutics’ Extraordinary General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
22 October, 2024 Egetis participates at medical conferences to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
4 October, 2024 Change in the Board of Directors of Egetis Therapeutics News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
30 September, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
30 September, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
30 September, 2024 Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
19 September, 2024 Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol News Corporate Information Other Corporate Information English IR Optional
6 September, 2024 Egetis highlights seven abstracts related to MCT8 deficiency, and two abstracts related to tiratricol and RTH-beta, published ahead of the Annual Meeting of the European Thyroid Association News Corporate Information Other Corporate Information English IR Optional
28 August, 2024 New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
22 August, 2024 Interim report Q2 2024 News English Regulatory MAR VPML Report Interim Q2 IR Optional
21 August, 2024 New data shows tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits News Corporate Information Other Corporate Information English IR Optional
14 August, 2024 Egetis submits responses to the European Medicines Agency’s Day 120 List of Questions for the Marketing Authorisation Application for tiratricol (Emcitate®) News Corporate Information Other Corporate Information English IR Optional
17 July, 2024 European Thyroid Association recommends tiratricol (Emcitate®) as long-term therapy for all patients with MCT8 deficiency in new guidelines News Corporate Information Other Corporate Information English IR Optional
19 June, 2024 Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
3 June, 2024 Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
6 May, 2024 Bulletin from Egetis Therapeutics’ Annual General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
3 May, 2024 Interim report Q1 2024 News English Regulatory MAR Report Interim Q1 IR Optional
24 April, 2024 The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ) News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
15 April, 2024 Egetis Therapeutics’ 2023 Annual Report published News English Regulatory VPML Report Annual IR Optional
29 March, 2024 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
Next

Calendar and upcoming reports

November 26, 2024
DNB Nordic Healthcare Conference (Oslo)

December 3, 2024
Redeye Technology & Life Science Day (Stockholm & online)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]